Novo Nordisk | Les Charges D'Exploitation



Operating Expenses Changement Date
ANI Pharmaceuticals USD 170.93M 24.02M 2025-03
Aurora Cannabis CAD 51.98M 31.53M 2024-12
Bausch Health Companies USD 1.98B 32M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Canopy Growth CAD 98.58M 10.03M 2024-12
Corcept Therapeutics USD 153.8M 2.83M 2025-03
Drreddys Laboratories INR 64.87B 2.26B 2024-12
Eli Lilly USD 7.32B 1.06B 2025-03
GlaxoSmithKline GBP 5.3B 2.12B 2025-03
Merck USD 9.66B 1.67B 2025-03
Novartis USD 11.28B 1.73B 2024-12
Novo Nordisk 39.3B 1.81B 2025-03
Novo Nordisk DKK 37.49B 4.64B 2024-09
Pacira USD 166.93M 4.38M 2025-03
Perrigo USD 1.03B 13.4M 2024-12
Prestige Brands USD 208.09M 9.74M 2025-03
Sanofi EUR 8.32B 1.55B 2025-03
Supernus Pharmaceuticals USD 152.75M 17.91M 2024-12
Zoetis USD 1.41B 175M 2025-03



Novo Nordisk Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.